Anti-tumor effect of L-deprenyl is associated with enhanced central and peripheral neurotransmission and immune reactivity in rats with carcinogen- induced mammary tumors

Journal of Neuroimmunology

Volumn 109, Issue 2, 2000, Pages 95-104

  Thyagarajan, S ^a   Madden, K S ^b   Stevens, S Y ^b   Felten, D L ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Catecholamines; Cytokines; Hypothalamus; NK cell activity; Selegiline; Tumor immunity

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CARCINOGEN; GAMMA INTERFERON; INTERLEUKIN 2; NORADRENALIN; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CARCINOGENESIS; CATECHOLAMINE NERVE CELL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOPAMINERGIC TRANSMISSION; FEMALE; HYPOTHALAMUS; IMMUNE RESPONSE; IMMUNOREACTIVITY; NATURAL KILLER CELL; NONHUMAN; NORADRENERGIC NERVE; PRIORITY JOURNAL; RAT; TUMOR IMMUNITY; TUMOR REGRESSION; TUMOR VOLUME;

3,4-DIHYDROXYPHENYLACETIC ACID; 9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMAL; CARCINOGENS; CELL DIVISION; FEMALE; FLOW CYTOMETRY; HYDROXYINDOLEACETIC ACID; IMMUNE SYSTEM; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS, NATURAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MONOAMINE OXIDASE INHIBITORS; NEUROIMMUNOMODULATION; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; SELEGILINE; SEROTONIN; SPLEEN; SUPPORT, U.S. GOV'T, NON-P.H.S.; SYMPATHETIC NERVOUS SYSTEM; SYNAPTIC TRANSMISSION; T-LYMPHOCYTES;

EID: 0034703188     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00305-2     Document Type: Article

References (40)

1. Addison L., Braciak T., Ralston R., Muller W.J., Gauldie J., Graham F.L. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sci. USA. 92:1995;8522-8526.
2. Bellinger D.L., Ackerman K.D., Felten S.Y., Felten D.L. A longitudinal study of age-related loss of noradrenergic nerves and lymphoid cells in the rat spleen. Exp. Neurol. 116:1992;295-311.
3. Bellinger D.L., Felten S.Y., Ackerman K.D., Lorton D., Madden K.S., Felten D.L. Noradrenergic sympathetic innervation of lymphoid organs during development, aging, and in autoimmune disease. Amenta F. Aging of the Autonomic Nervous System. 1993;243-284 CRC Press, Boca Raton, FL.
4. Bindoni M., Belluardo N., Licciardello S., Marchese A.E., Cicirata F. Growth of Yoshida ascites tumor in the rat after radiofrequency destruction of the tuberoinfundibular region of the hypothalamus. Neuroendocrinology. 30:1980;88-93.
5. Cano G., Sved A.F., Rinaman L., Rassnick S., Rabin B.S., Card J.P. Transynaptic analysis of the CNS innervation of rat spleen (Abstract). Soc. Neurosci. Abstr. 23:(2):1997;1508.
6. Carrillo M.C., Kitani K., Kanai S., Sato Y., Miyasaka K., Ivy G.O. The effect of a long term (6 months) treatment with (-)-deprenyl on antioxidant enzyme activities in selective brain regions in old female Fischer 344 rats. Biochem. Pharmacol. 47:1994;1333-1338.
7. Cawein M.J., Sydnor K. Suppression of cellular activity in the reticuloendothelial system of the rat by 7,12-dimethylbenz(a)anthracene. Cancer Res. 28:1968;320-327.
8. Demarest K.T., Moore K.E. Lack of high affinity transport system for dopamine in the median eminence and posterior pituitary. Brain Res. 171:1979;545-551.
9. Dickson R.B., Lippman M.E. Molecular determinants of growth, angiogenesis, and metastases in breast cancer. Semin. Oncol. 19:1992;286-298.
10. Felten D.L., Cohen N., Ader R., Felten S.Y., Carlson S.L., Roszman T.L. Central and neural circuits involved in neural-immune interactions. Ader R., Felten D.L., Cohen N. Psychoneuroimmunology. 2nd Edition :1991;3-25 Academic Press, New York.
11. Forni G., Bindoni M., Santoni A., Belluardo N., Marchese A.E., Giovarelli M. Radiofrequency destruction of the tuberoinfundibular region of hypothalamus permanently abrogates NK cell activity in mice. Nature. 306:1983;181-184.
12. Gallo F., Morale M.C., Sambataro D., Farinella Z., Scapagnini U., Marchetti B. The immune system response during development and progression of carcinogen-induced rat mammary tumors: prevention of tumor growth and restoration of immune system responsiveness by thymopentin. Breast Cancer Res. Treat. 27:1993;221-237.
13. Gudelsky G.A., Metzer H.Y. Function of tuberoinfundibular dopamine neurons in pargyline- and reserpine-treated rats. Neuroendocrinology. 38:1984;51-55.
14. Herberman R.B., Holden H.T. Natural cell-mediated immunity. Adv. Cancer Res. 27:1978;305-315.
15. Kearney R., Hughes L.E. The effect of tumor growth on immunocompetence. A study on DMBA mammary carcinogenesis in the rat. Br. J. Cancer. 24:1970;319-327.
16. Knoll J. Deprenyl (Selegiline): the history of its development and pharmaceutical action. Acta Neurol. Scand. Suppl. 95:1980;57-80.
17. L'Abbe M.R., Fischer P.W., Chavez E.R. Changes in selenium and antioxidant status during DMBA-induced mammary carcinogenesis in rats. J. Nutr. 119:1989;766-771.
18. Madden K.S., Felten S.Y., Felten D.L., Sundaresan P.R., Livnat S. Sympathetic nervous system modulation of the immune system. I. Depression of T cell immunity in vivo and in vitro following chemical sympathectomy. Brain Behav. Immun. 3:1989;72-79.
19. Madden K.S., Moynihan J.A., Brenner G.J., Felten S.Y., Felten D.L., Livnat S. Sympathetic nervous system modulation of the immune system. III. Alterations in T and B cell proliferation and differentiation in vitro following chemical sympathectomy. J. Neuroimmunol. 49:1994;77-87.
20. Madden K.S., Sanders V.M., Felten D.L. Catecholamine influences and sympathetic neural modulation of immune responsiveness. Annu. Rev. Pharmacol. Toxicol. 35:1995;417-448.
21. Meites J. Relation of the neuroendocrine system to the development and growth of experimental mammary tumors. J. Neural Transm. 48:1980;25-42.
22. MohanKumar P.S., Meites J., Quadri S.K. Deprenyl reduces serum prolactin concentrations in rats. Life Sci. 54:1994;841-845.
23. Monte M., Davel L.E., de Lustig E.S. Inhibition of lymphocyte-induced angiogenesis by free radical scavengers. Free Radic. Biol. Med. 17:1994;259-266.
24. Pahlavani M.A., Richardson A. The effect of age on the expression of interleukin-2. Mech. Ageing Dev. 89:1996;125-154.
25. Quadri S.K., Clark J.L., Meites J. Effects of LSD, pargyline and haloperidol on mammary tumor growth in rats. Proc. Soc. Exp. Biol. Med. 142:1973;22-26.
26. Seinuk N.A., Henderson J.T., Tatton W.G., Roder J.C. Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R-(-)-deprenyl. J. Neurosci. Res. 37:1994;278-286.
27. Souberbielle B., Dalgleish A. Anti-tumor immune mechanisms. Lewis C.E., O'Sullivan C., Barraclough J. The Psychoimmunology of Cancer - Mind and Body in the Fight For Survival? 1994;267-290 Oxford University Press, New York.
28. Tariot P.N., Sunderland T., Weingartner H., Murphy D.L., Welkowitz J.A., Thompson K., Cohen R.M. Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology. 91:1987;489-495.
29. Tetrud J.W., Langston J.W. The effect of deprenyl on the natural history of Parkinson's disease. Science. 245:1989;519-522.
30. ThyagaRajan S., Meites J., Quadri S.K. Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decreases the incidence of mammary and pituitary tumors in old acyclic rats. Endocrinology. 136:1995;1103-1110.
31. ThyagaRajan S., Felten S.Y., Felten D.L. Anti-tumor effect of deprenyl in rats with carcinogen-induced mammary tumors. Cancer Lett. 123:1998;177-183.
32. ThyagaRajan S., Madden K.S., Kalvass J.C., Dimitrova S., Felten S.Y., Felten D.L. L-deprenyl-induced increase in IL-2 and NK cell activity accompanies restoration of noradrenergic nerve fibers in the spleens of old F344 rats. J. Neuroimmunol. 92:1998;9-21.
33. ThyagaRajan S., Madden K.S., Stevens S.Y., Felten D.L. Effects of L-deprenyl treatment on noradrenergic innervation and immune reactivity in lymphoid organs of young F344 rats. J. Neuroimmunol. 96:1999;57-65.
34. ThyagaRajan S., Quadri S.K. L-Deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors. Endocrine. 10:1999;225-232.
35. ThyagaRajan S., Madden K.S., Stevens S.Y., Felten D.L. Inhibition of tumor growth by L-deprenyl involves neural-immune interactions in rats with spontaneously developing mammary tumors. Anticancer Res. 19:1999;5023-5028.
36. Watanabe Y. Transfection of interferon-gamma gene in animal tumors - a model for local cytokine production and tumor immunity. Semin. Cancer Biol. 3:1992;43-46.
37. Welsch C.W., Nagasawa H. Prolactin and mammary tumorigenesis: a review. Cancer Res. 37:1977;951-963.
38. Westfall T.C., Naes L., Paul C. Relative potency of dopamine agonists on autoreceptor function in various brain regions of the rat. J. Pharmacol. Exp. Ther. 224:1983;199-205.
39. Whiteside C., Blackmon R.H., Bremner T.A. Estrogen regulation of superoxide dismutase in normal rat mammary tissues and mammary tumors. Biochem. Biophys. Res. Commun. 113:1983;883-887.
40. Won S.J., Lin M.T. Alpha-methyl-p-tyrosine reduces poly I:C-induced augmenting interferon production and splenic natural killer cell activity. Pharmacology. 46:1993;332-340.